Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.820
+0.060 (3.41%)
At close: Oct 9, 2025, 4:00 PM EDT
1.830
+0.010 (0.55%)
Pre-market: Oct 10, 2025, 7:22 AM EDT
Coherus Oncology Revenue
Coherus Oncology had revenue of $10.25M in the quarter ending June 30, 2025, a decrease of -0.41%. This brings the company's revenue in the last twelve months to $142.77M, down -20.10% year-over-year. In the year 2024, Coherus Oncology had annual revenue of $266.96M with 3.78% growth.
Revenue (ttm)
$142.77M
Revenue Growth
-20.10%
P/S Ratio
0.77
Revenue / Employee
$1,193,899
Employees
228
Market Cap
211.53M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 266.96M | 9.72M | 3.78% |
Dec 31, 2023 | 257.24M | 46.20M | 21.89% |
Dec 31, 2022 | 211.04M | -115.51M | -35.37% |
Dec 31, 2021 | 326.55M | -149.27M | -31.37% |
Dec 31, 2020 | 475.82M | 119.75M | 33.63% |
Dec 31, 2019 | 356.07M | - | - |
Dec 31, 2018 | - | - | - |
Dec 31, 2017 | 1.56M | -188.55M | -99.18% |
Dec 31, 2016 | 190.11M | 160.07M | 532.82% |
Dec 31, 2015 | 30.04M | -1.07M | -3.42% |
Dec 31, 2014 | 31.11M | 28.36M | 1,030.72% |
Dec 31, 2013 | 2.75M | 852.00K | 44.87% |
Dec 31, 2012 | 1.90M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CHRS News
- 6 days ago - Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - GlobeNewsWire
- 8 days ago - Coherus Oncology, Inc. (CHRS) Presents at UBS Virtual Oncology Day Transcript - Seeking Alpha
- 8 days ago - Coherus Oncology: Five Readouts Or More Possible In 2026 - Seeking Alpha
- 6 weeks ago - Coherus Oncology: On The Shaping Up - Seeking Alpha
- 2 months ago - Coherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 - GlobeNewsWire
- 5 months ago - Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript - Seeking Alpha